Abcellera Biologics Inc (ABCL)vsargenx NV ADR (ARGX)
ABCL
Abcellera Biologics Inc
$12.65
-0.08%
HEALTHCARE · Cap: $3.39B
ARGX
argenx NV ADR
$963.79
-2.47%
HEALTHCARE · Cap: $61.92B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 7933% more annual revenue ($5.32B vs $66.17M). ARGX leads profitability with a 32.3% profit margin vs -248.8%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ABCL
Avoid27
out of 100
Grade: F
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.4%
Fair Value
$6.87
Current Price
$12.65
$5.78 discount
Margin of Safety
+64.8%
Fair Value
$2372.23
Current Price
$963.79
$1408.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Earnings expanding 45.9% YoY
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
ROE of -15.3% — below average capital efficiency
Revenue declined 76.3%
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 179.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Debt/Equity, EPS Growth.
Bull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bear Case : ABCL
The primary concerns for ABCL are Altman Z-Score, Return on Equity, Revenue Growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ABCL profiles as a turnaround stock while ARGX is a growth play — different risk/reward profiles.
ABCL carries more volatility with a beta of 1.32 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 27/100), backed by strong 32.3% margins and 59.3% revenue growth. ABCL offers better value entry with a 54.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?